Marker Therapeutics Inc (MRKR)

[Phantom Lord]

Protocol is to suspend enrollment into the trial while they dose the first set of patients. In this case the study size was initially set to 40 patients. They enrolled 27 and, per standard procedure, stopped enrolling new participants while they conduct the interim analysis. At this point that analysis should be done and the interim data should be available. We will have to wait until the conference call to know for sure what's going on. Once the interim analysis is complete they open enrollment back up to complete the trial. Don't know where they are now but the last update to clinicaltrials.gov was in March of this year.